BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30382056)

  • 1. [Indoleamine 2,3-Dioxygenase Activity during Long-Term Letrozole Therapy for Hormone Receptor-Positive Breast Cancer].
    Suzuki Y; Sakurai K; Adachi K; Kubota H; Suzuki S; Takei S; Hara Y; Enomoto K; Hirano T; Makishima M
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1495-1497. PubMed ID: 30382056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indoleamine 2,3-Dioxygenase Activity during Letrozol Therapy for an Elderly Breast Cancer Patient].
    Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):892-895. PubMed ID: 29066687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy].
    Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S; Shiono M
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2265-7. PubMed ID: 19106591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indoleamine 2, 3-dioxygenase activity during neoadjuvant chemotherapy in patients with breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1578-80. PubMed ID: 24393854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Indoleamine 2,3-Dioxygenase Activity in Intracystic Breast Tumors].
    Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Enomoto K; Hirano T; Tomita R; Gonda K
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1295-1297. PubMed ID: 27760965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Shibata M; Gonda K; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1791-3. PubMed ID: 23267888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
    Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Hirano T; Enomoto K; Tomita R; Gonda K
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1233-1236. PubMed ID: 27760945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Indoleamine 2, 3-dioxygenase activity for breast cancer patients with recurrence 5 or more years after surgery].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1590-2. PubMed ID: 24393858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1286-8. PubMed ID: 25335719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
    Sakurai K; Fujisaki S; Suzuki S; Adachi K; Nagashima S; Masuo Y; Tomita R; Gonda K; Enomoto K; Amano S; Matsuo S; Umeda N
    Gan To Kagaku Ryoho; 2015 Oct; 42(10):1225-7. PubMed ID: 26489554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor Resistant Metastatic Breast Cancer].
    Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):886-888. PubMed ID: 29066685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Shibata M; Maeda T; Ueda Y; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1930-2. PubMed ID: 22202242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer].
    Sakurai K; Matsuo S; Enomoto K; Tani M; Kitajima A; Amano S
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1991-3. PubMed ID: 20037301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
    Sakurai K; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2252-4. PubMed ID: 21224538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indoleamine 2,3-dioxygenase activity in breast cancer patients with local recurrence or distant metastases].
    Sakurai K; Fujisaki S; Suzuki S; Nagashima S; Maeda T; Tomita R; Hara Y; Hirano T; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1304-6. PubMed ID: 25335725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy.
    Onesti CE; Boemer F; Josse C; Leduc S; Bours V; Jerusalem G
    J Transl Med; 2019 Jul; 17(1):239. PubMed ID: 31337401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indoleamine 2,3-Dioxygenase Activity during I131-Radioisotope Therapy for Metastatic Thyroid Cancer].
    Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Tomita R; Gonda K; Hirano T; Enomoto K
    Gan To Kagaku Ryoho; 2015 Oct; 42(10):1259-61. PubMed ID: 26489565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
    J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical Evaluation of Indoleamine 2, 3-Dioxygenase in the Serum of Patients with Locally Advanced Breast Cancer during Mohs Paste Treatment].
    Kubota H; Sakurai K; Fujisaki S; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):915-917. PubMed ID: 29066694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
    Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
    Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.